Savara

Clinical-stage biopharmaceutical company focused on rare respiratory diseases

Built from URL

HealthcarePharmaceuticals & MedicineClinical TrialsLife SciencesBiotechDrug Discovery

AboutBuilt from URL

Savara is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Their lead product candidate is MOLBREEVI, an inhaled recombinant GM-CSF therapy in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

ProblemBuilt from URL

People living with rare respiratory diseases, particularly autoimmune pulmonary alveolar proteinosis (aPAP), need improved treatment options.

See something off about this company?